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Recently, we identified a bovine IgA Fc receptor
(bFcR), which shows high homology to the human my-
eloid FcR, CD89. IgA binding has previously been
shown to depend on several specific residues located in
the B-C and F-G loops of the membrane-distal extracel-
lular domain 1 of CD89. To compare the ligand binding
properties of these two FcRs, we have mapped the IgA
binding site of bFcR. We show that, in common with
CD89, Tyr-35 in the B-C loop is essential for IgA binding.
However, in contrast to earlier observations on CD89,
mutation of residues in the F-G loop did not signifi-
cantly inhibit IgA binding.
Circulating human phagocytes constitutively express an Fc
receptor for immunoglobulin A (IgA),1 which has been desig-
nated FcRI or CD89. The binding of IgA-coated targets such
as bacteria and viruses to CD89 has been shown to trigger a
variety of cellular effector functions including phagocytosis,
antibody-dependent cellular cytotoxicity, respiratory burst,
and synthesis and release of cytokines. Furthermore, mounting
experimental evidence suggests that CD89 is able to trigger
cellular effector functions, at least as well as and perhaps even
better than IgG Fc receptors (FcRs). Therefore, CD89 provides
a crucial link between the humoral and cellular arms of the
immune system, which may in the future be exploited for
therapeutic purposes (1).
A better understanding of the biological role of FcRs has
benefited greatly from the fact that cDNAs encoding the three
receptor classes, FcRI/CD64, FcRII/CD32, and FcRIII/
CD16, have been cloned and characterized from several differ-
ent species (2–4). Such comparative studies have not been
possible for CD89, because only this human FcR has been
available for study. Recently, however, we cloned an FcR
homologous to CD89 from cattle and called it bFcR (5).
CD89 and bFcR are closely related to both the killer cell
immunoglobulin-like receptors (KIRs) and the leukocyte immu-
noglobulin-like receptors. The human CD89, KIR, and leuko-
cyte immunoglobulin-like receptors genes have been mapped to
a region of chromosome 19 called the leukocyte receptor com-
plex (LRC) (6). Similarly, the bFcR gene has been localized to
the bovine LRC on chromosome 18 (5). The closest FcR relative
to CD89 and bFcR is the bovine FcR for IgG2 (bFc2R) whose
gene is probably also located in the bovine LRC (7, 8).
CD89 and bFcR are type I transmembrane glycoproteins,
and each possesses two extracellular (EC) Ig-like domains (1,
9). They are both predicted to have a 19-amino acid transmem-
brane region containing a positively charged arginine residue,
which at least for CD89 has been shown to be necessary for
association with the common FcR -chain (10). Although much
remains to be learned regarding the biological role of bFcR,
the presence of a charged transmembrane residue implies that
this receptor is able to recruit specialized signaling molecules
and thus probably represents a potent triggering molecule on
bovine cells. Both receptors also have short cytoplasmic tails
lacking other recognized signaling motifs. A further striking
characteristic of CD89 (and also the closely related bFc2R) is
that, in contrast to other FcRs, the ligand binding site is located
in the membrane distal EC1 domain (11–14). In this study, we
have used mutational analysis to map the IgA binding site of
bFcR. Our data revealed that mutation of a single residue in
the B-C loop abolished the interaction with bovine IgA. In
addition, the mutation of residues in the F-G loop, which have
been shown to be important in ligand binding by CD89, did not
appear to affect binding.
EXPERIMENTAL PROCEDURES
Cell Culture—COS-1 cells were maintained in Dulbecco’s modified
Eagle’s medium (BioWhittaker, Walkserville, MD) supplemented with
10% fetal calf serum, 1 mM L-glutamine, and 50 g/ml gentamycin
(Invitrogen).
Immunoglobulin Preparations—Purified bovine IgA (bIgA) was pur-
chased from Inter-Cell Technologies Inc. (Hopewell, NJ). The construc-
tion of the relevant expression vectors, generation of Ig secreting cell
lines, and purification of recombinant anti-NIP bIgA have been de-
scribed previously (15). Recombinant human anti-NIP IgA was also
purified at LIIPAT and was kindly provided by Drs. R. Braathen and
F.-E. Johansen (16).
Plasmid Construction and Generation of bFcR Mutants—A plasmid
containing an HA-tagged variant of the human FcRn cDNA subcloned
immediately downstream of the murine major histocompatibility com-
plex I Kb signal sequence (17) was kindly provided by Dr. F.-E.
Johansen.
To generate bFcR containing an NH2-terminal HA tag (5-YPYDVP-
DYA-3), overlap extension PCR was performed to fuse the major histo-
compatibility complex I Kb signal sequence and HA tag in-frame with the
nucleotide sequence encoding the mature bFcR protein. The resultant
PCR product was then subcloned into the pcDNA3.1/V5-His-TOPO
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vector. Plasmids containing the HA-bFcR cDNA in the correct orien-
tation were selected by restriction enzyme digestion, and the nucleotide
sequence was verified by sequencing. Prior to the generation of addi-
tional mutants, the functionality of the wild-type HA-bFcR cDNA was
further verified by transfection into COS-1 cells. This finding demon-
strated that HA-bFcR was expressed at the cell surface and was able
to bind IgA. Point mutations were introduced into HA-bFcR with the
QuikChange mutagenesis kit (Stratagene) and appropriate synthetic
oligonucleotides. The integrity of all of the mutants was confirmed by
sequence analysis prior to transfection.
The pCMV-GFP plasmid, encoding the green fluorescent protein,
was constructed by inserting the cytomegalovirus (CMV) promoter re-
gion from pCDNA3 (Invitrogen) into the multiple cloning site of the
pEGFP-1 vector (Clontech, Palo Alto, CA).
Transfections—COS-1 cells were transiently transfected with 1 g of
bFcR cDNA constructs by means of FuGENE 6 transfection reagent
(Roche Applied Science) according to the manufacturer’s instructions.
Cells to be used for Ig binding assays were co-transfected with 0.05 g
of the pCMV-GFP plasmid in addition to the bFcR constructs. Cells
were incubated at 37 °C in a humidified CO2 atmosphere for 48 h prior
to harvesting.
Ig Binding Assays—Uncoated magnetic M-450 Dynabeads (Dynal,
Oslo, Norway) were coated with NIP-bovine serum albumin according
to the manufacturer’s instructions. To prepare beads coated with re-
combinant human or bovine (anti-NIP) IgA, NIP-bovine serum albu-
min-coated beads were incubated with 100 g/ml IgA for 1 h at room
temperature. These beads were washed three times in phosphate-buff-
ered saline prior to rosetting analysis. In our rosetting procedure,
COS-1 cells were co-transfected with a bFcR construct and pCMV-
GFP. In this way, the COS-1 cells, which had taken up DNA during the
transfection procedure, could be readily identified by their green fluo-
rescence. In addition, untransfected cells that did not take up DNA and
were thus not green served as an internal negative control of binding.
The binding assays were performed as follows: 0.5  105 trans-
fected COS-1 cells were mixed with Ig-coated Dynabeads in a final
volume of 50 l per well in V-bottomed microtiter plates. After a 20-min
incubation at room temperature, the plate was spun at 50  g for 1 min
and incubated for an additional 45 min at room temperature. Cells and
beads were then carefully resuspended and examined for the presence
of rosettes in a Nikon Eclipse E800 microscope, combining ordinary
light and fluorescence.
FACS Analysis—To assess the expression of the HA-bFcR mutants
at the cell surface, COS-1 cells transfected with only the HA-bFcR
cDNAs (and not the GFP construct) were washed twice with FACS
buffer (phosphate-buffered saline, 0.5% bovine serum albumin, 0.02%
azide) and incubated with the HA.11 anti-HA tag monoclonal antibody
(mAb) (mIgG1; Biosite, Ta¨by, Sweden) or an irrelevant mIgG1 mAb
(Southern Biotechnology, Birmingham, AL) as control for 30 min at
4 °C. Cells were next washed twice with FACS buffer and incubated for
30 min at 4 °C with goat anti-mouse IgG1-fluorescein isothiocyanate
conjugate (Southern Biotechnology). After washing twice with FACS
buffer, cells were analyzed on a FACScan (BD Biosciences). Data ac-
quisition was conducted with CELLQuest software (BD Biosciences),
whereas the analysis was performed with WinMDI software (available
from the Scripps Research Institute, La Jolla, CA).
RESULTS
Construction and Expression of HA-bFcR—COS-1 cells
transfected with bFcR cDNA are able to form rosettes with
beads coated with bovine and human IgA (5), but a specific
antibody reagent recognizing the bFcR protein is not avail-
able. Therefore, we were unable to independently verify surface
expression of bFcR. Consequently, we decided to generate a
bFcR containing an NH2-terminal HA tag that would allow
detection of the expressed protein with a mAb against HA.
Following the transfection of HA-bFcR into COS-1 cells, we
showed that the protein was indeed expressed at the cell sur-
face and was recognized by a mAb specific for the HA tag (Fig.
1). In addition, we showed that COS-1 cells expressing HA-
bFcR were able to bind to beads coated with either bovine or
human IgA. Moreover, the pattern of binding was indistinguish-
able from that observed with cells transfected with the wild-type
bFcR (Fig. 2). Altogether, these result strongly suggested that
the incorporation of the HA tag into the NH2-terminal of bFcR
did not adversely affect its ability to bind IgA.
Identification of Residues Important for IgA Binding—Pre-
vious mutational analysis of FcRs most closely related to
bFcR, namely CD89 and bFc2R, has identified several resi-
dues within their EC1 domains important for ligand binding
(11, 13, 14). For CD89, these studies have shown that residues
Tyr-35 (in the B-C loop) and Arg-82 (in the F-G loop) are
essential for IgA binding, whereas His-85 (also in the F-G loop)
contributes to the binding (Fig. 3). Similarly, for bFc2R, two
residues in the F-G loop, Phe-82 and Trp-87, have been shown
to be critical for the binding of bIgG2. The amino acid align-
ment of the protein sequence of CD89 and bFcR showed that
the tyrosine residue at position 35 is conserved. Notably, the
arginine and histidine residues within the F-G loop of bFcR
are also conserved, although due to a two-amino acid deletion
earlier in the domain, they are designated Arg-80 and His-83,
respectively (Fig. 3). In addition, the residues toward the end of
the bFcR EC1 F-G loop are actually more similar to the
corresponding residues of bFc2R (WSAPSE compared with
WSEPSE, respectively).
Therefore, to identify the IgA binding site of bFcR, we
decided to mutate residues corresponding to those amino acids
FIG. 2. IgA binding by bFcR, HA-bFcR, and CD89. Rosetting
analysis was performed with COS-1 cells expressing the indicated
FcR. The beads were coated with either bovine (Bov IgA,white bars) or
human IgA (Hum IgA, gray bars). The results shown are representative
of at least three separate experiments.
FIG. 1. Surface expression of HA-tagged bFcR. COS-1 cells
were transfected with either wild-type bFcR or HA-bFcR. Trans-
fected COS-1 cells were then harvested and stained with an irrelevant
isotype-matched control antibody (top two panels) or with an anti-HA
mAb (bottom two panels) followed by an appropriate fluorescein isothio-
cyanate-labeled secondary reagent. FSC, forward scatter.
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within CD89 and bFc2R that had been previously identified as
important for ligand binding. A panel of four mutants was
generated. Tyr-35, Arg-80, His-83, and Trp-85 were all re-
placed with Ala residues to generate the Y35A, R80A, H83A,
and W85A mutants, respectively. Mutated HA-bFcR cDNAs
were then transfected into COS-1 cells, and their surface ex-
pression was confirmed by staining with the anti-HA mAb (Fig.
4). Although the W85A mutant appears to be expressed on a
lower percentage of cells than the other mutants, the expres-
sion levels were more than sufficient for rosette analysis.
COS-1 cells expressing the mutated HA-bFcR cDNAs were
assayed for their ability to form rosettes with IgA-coated beads.
We found that cells expressing the R80A, H83A, and W85A
mutants were still able to bind to beads coated with either
bovine or human IgA. In fact, only the cells expressing the
Y35A mutant proved completely unable to form rosettes with
IgA-coated beads (Fig. 5). These results showed that Tyr-35,
which is predicted to lie within the B-C loop of the EC1 domain
of bFcR, is essential for IgA binding. Interestingly, the muta-
tion of residues within the F-G loop, namely Arg-80, His-83,
and Trp-85, did not appear to adversely affect ligand binding by
bFcR.
DISCUSSION
Here, we report that mutation of a single residue (Tyr-35) in
the B-C loop of the EC1 domain of bFcR was sufficient to
abolish the interaction with IgA. Somewhat surprisingly and in
contrast to previous reports describing similar mutations of
CD89, we also showed that mutation of residues in the F-G loop
region (Arg-80, His-83, and Trp-85) had no or little apparent
effect on IgA binding in our assay system.
The bFcR, CD89, and bFc2R represent a unique class of
FcRs and are only distantly related to other mammalian FcRs
such as FcRI, FcRII, FcRIII, and FcRI (1). In fact, they are
more closely related to the family of genes that includes the
KIRs, the leukocyte immunoglobulin-like receptors, and
NKp46. In humans, the CD89 gene is located close to the KIR,
leukocyte immunoglobulin-like receptor, and NKp46 genes
within the so-called LRC on chromosome 19q13.4 (18, 19). It
has been shown that the KIR and NKp46 genes are present in
cattle, and these genes are also located in the bovine LRC on
chromosome 18 (20, 21). Recently, we have also mapped the
bFcR gene to the bovine LRC (5).
Reflecting this differential evolution, it had previously been
shown that CD89 and bFc2R shared various characteristics,
which further distinguished them from other FcRs. One such
unique feature is that the Ig binding site of these two FcRs lies
in the EC1 domain (12), whereas that of other FcRs (FcRs and
FcRI) lies predominantly in the EC2 domain (22–24). Specific
residues within the EC1 domains of CD89 and bFc2R have
been identified by site-directed mutagenesis studies. Thus, for
CD89 expressed at the cell surface, it has been shown that
Tyr-35 in the B-C loop and Arg-82 in the F-G loop are essential
for binding to IgA (11, 13). Biosensor data have also suggested
that His-85 is critical for IgA binding, but the effect of mutation
of this residue on binding by cell surface-expressed receptor
has not been reported (11, 13).
In the case of bFc2R, ligand binding appears to depend on
two residues in the F-G loop region and mutation of either
Phe-82 or Trp-87 abolishes binding to bovine IgG2 (14). Thus,
by comparison with other closely related FcRs, we identified a
number of residues that we believe may be important for IgA
FIG. 5. IgA binding by HA-bFcR mutants. Rosetting analysis
was performed with COS-1 cells expressing HA-bFcR with the indi-
cated mutations. The beads were coated with either bovine (Bov IgA,
white bars) or human IgA (Hum IgA, gray bars). The results shown are
representative of at least three separate experiments.
FIG. 3. A, alignment of the protein sequences of the EC1 domains of
bFcR, CD89, and bFc2R (NCBI protein accession numbers
AAP41842, CAA38089, and CAA85736, respectively). B-sheet regions of
CD89 (designated A to F) by broken arrows under the sequence (based
on data from Refs. 19 and 20). The numbering system used for the
amino acid sequence of bFcR in this report is indicated in detail above
the text. Note that the numbering of CD89 is identical to bFcR up to
amino acid 57, after which there is a two-residue insertion in CD89. The
numbering system used for bFc2R is consistent with that used in
earlier publications and reflects the prediction that the bFc2R leader
peptide is two amino acids shorter than those of bFcR and CD89
(see Refs. 7 and 14). The amino acids previously identified as important
for the binding of IgA to CD89 only are marked with a . The amino
acids previously identified as important for binding of IgA and bIgG2 to
CD89 and bFc2R, respectively, are indicated with a  (see Refs. 11, 13,
and 14).
FIG. 4. Surface expression of the HA-tagged bFcR mutants.
COS-1 cells were transfected with four differently mutated HA-tagged
bFcR cDNAs as indicated. Two days thereafter, the cells were har-
vested and stained with an anti-HA mAb. Mock-transfected cells were
used as control. FSC, forward scatter.
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binding by bFcR. Therefore, we chose to mutate Tyr-35, Arg-
80, His-83, and Trp-85 and investigate the effect on the inter-
action with IgA. Although slightly different numbering systems
were used for these three FcRs, the sequence homology pre-
dicted that Arg-80 and His-83 of bFcR correspond to Arg-82
and His-85 of CD89. Similarly, bFcR Trp-85 corresponds to
Trp-87 of bFc2R (see Fig. 3).
To correctly interpret our IgA binding assays, we required an
independent method to confirm the surface expression of the
bFcR mutants. Traditionally, such mutagenesis studies of
FcRs have depended on specific anti-FcR mAbs to confirm
surface expression of the mutated receptors (13, 14). However,
in the case of bFcR, there was no specific mAb available.
Therefore, we decided to introduce an HA tag into the NH2
terminus of the receptor. Previously, it has been shown that the
NH2 terminus of CD89 does not contribute in any way to the
IgA binding site and we reasoned that this would most likely
also be the case for the highly homologous bFcR (13). Indeed,
our data showed that the introduction of the HA tag into bFcR
had no apparent effect on the ability of transfected COS-1 cells
to bind IgA-coated beads. Consequently, we proceeded to intro-
duce the previously specified mutations into the HA-tagged
version of bFcR.
Our results showed that, in common with CD89, Tyr-35 in
the B-C loop of the EC1 domain of bFcR appears to be essen-
tial for the binding of IgA. Surprisingly, however, the substi-
tution of residues in the F-G loop region with alanine did not
inhibit binding to IgA-coated beads. The mutation of Arg-82 to
alanine in CD89 has been reported to abolish IgA binding, so
we had expected that the corresponding mutation in bFcR
(R80A) would have a similar effect. However, although alanine
substitutions in the F-G loop of bFcR did not abolish binding,
we cannot exclude that residues in this region contribute some-
what to the interaction with ligand. Previously, the biosensor
analysis of CD89 mutants also identified Arg-52 as a residue
that appeared to contribute to IgA binding. Biosensor data
showed that the mutation of Arg-52 to alanine produced an
8-fold reduction in affinity. However, when this mutant was
expressed at the cell surface, it still bound the same amounts of
IgA as wild-type CD89 (13). Thus, biosensor measurements
with mutated soluble proteins, which show even a relatively
large reduction in affinity, may not necessarily indicate how
the binding reaction will proceed when a mutated FcR is ex-
pressed at the cell surface and assayed for binding to Ig-coated
particles, a situation presumably mimicking more closely FcR-
mediated cellular triggering in vivo. In this respect, the sensi-
tivity of our rosetting method may be advantageous because it
allows us to detect mutations that completely abolish binding
and are thus essential for promoting the CD89-IgA interaction.
Unfortunately, however, this assay does not readily detect very
small changes in affinity so we cannot rule out the possibility
that residues in the F-G loop do make a minor contribution to
the interaction with IgA. However, our data clearly show that
the residues in the F-G loop, which were mutated in this study,
are not essential for the binding of IgA-coated particles to
CD89-expressing cells.
Recently, the three-dimensional structure of CD89 was
solved (25, 26). More interestingly, the structure of CD89 in
complex with the IgA Fc and the stoichiometry of the reaction
were elucidated (25, 27). Unlike the FcRs and FcRI, which
bind Ig with a 1:1 stoichiometry, two CD89 molecules were
shown to bind one IgA Fc region. The co-crystal data further
confirmed that residues such as Tyr-35 and Arg-82, which had
previously been shown to be involved in IgA binding by mu-
tagenesis, do indeed directly contact the IgA Fc.
The high level of homology between CD89 and bFcR sug-
gests that their overall structures will be similar. In addition,
the residues within the Fc region of human IgA, which have
been shown to interact with CD89, are also conserved in the
bovine IgA Fc (15). Taken together, these data suggest that
bFcR binds IgA in a manner broadly similar to CD89 (Fig. 6).
However, our results suggest that in contrast to the situation
for CD89, the F-G loop of the EC1 domain of bFcR may not
play an essential role in IgA binding.
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